35 peer-reviewed studies spanning stem cells, exosomes, neurology, and nanoparticle delivery systems. The scientific foundation behind NeoRegen Biosciences' mission to restore, repair, and regenerate.
Each research domain represents a critical component of NeoRegen Biosciences' evidence base, from cellular therapy and neurological regeneration to advanced delivery systems.
Mesenchymal stem cell therapy for osteoarthritis and joint repair represents one of the most actively investigated areas in regenerative orthopedics. These studies form the evidence base for MSC-based intra-articular treatments, spanning Phase I through Phase III clinical trials, systematic reviews, and dose-optimization research.
1
Intra-articular Injection of Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee: A Proof-of-Concept Clinical Trial
Jo CH, Lee YG, Shin WH, et al.Stem Cells2014
Phase I/II dose-escalation trial evaluating adipose-derived MSCs for knee OA across three dose cohorts (1×10⁷, 5×10⁷, 1×10⁸ cells). Eighteen patients with Kellgren-Lawrence grade 3–4 OA.
High-dose group: WOMAC scores decreased by 39%, VAS pain dropped from 62 to 31 mm, MRI confirmed hyaline-like cartilage regeneration. Zero serious adverse events across all dose levels.
NeoRegen Relevance: Establishes dose-response relationship for MSC therapy in OA. The finding that 1×10⁸ cells is the threshold for cartilage regeneration directly informs product concentration targets for orthopedic applications.
Mesenchymal Stem Cells in the Treatment of Human Articular Cartilage Defects: A Systematic Review
Goldberg A, Mitchell K, Soans J, et al.Journal of Orthopaedic Research2017
Systematic review of 17 clinical studies (582 patients) evaluating MSC treatment for articular cartilage defects, following PRISMA guidelines.
15 of 17 studies showed improved pain scores (40–60% VAS reduction). Cartilage regeneration on MRI in 9 of 12 studies. No serious adverse events attributable to MSC therapy across any study.
NeoRegen Relevance: Validates overall safety and efficacy of MSC-based joint therapies. The heterogeneity finding underscores the market opportunity for standardized, quality-controlled products.
Intra-articular Injection of Autologous Adipose-Derived MSCs vs Hyaluronic Acid for Knee OA: A Randomised Controlled Study
Freitag J, Bates D, Wickham J, et al.BMC Musculoskeletal Disorders2019
Pivotal RCT directly comparing adipose-derived MSCs against hyaluronic acid in 30 patients with KL grade 2–3 knee OA, randomized across three arms.
Both MSC groups showed statistically significant superiority over HA at 12 months. Two-injection MSC group: KOOS pain improved by 23.7 points (p<0.001 vs. HA). MRI showed cartilage quality improvement only in the two-injection group.
NeoRegen Relevance: Head-to-head superiority over HA—the current injectable standard of care—is the strongest clinical evidence supporting regenerative biologics in orthopedics.
Injection of Bone Marrow MSCs in Knee Osteoarthritis: A Randomized Controlled Trial with 12-Month Follow-Up
Lamo-Espinosa JM, Mora G, Blanco JF, et al.Stem Cells Translational Medicine2018
Phase I/II RCT with one of the most rigorous control designs: 30 patients randomized to low-dose BM-MSC + HA, high-dose BM-MSC + HA, or HA alone.
High-dose group achieved 72% VAS pain reduction at 12 months vs. 17% for HA alone (p<0.001). Range of motion increased +12 degrees. T2 MRI showed improved cartilage matrix. Zero serious adverse events.
NeoRegen Relevance: The 72% pain reduction in the high-dose arm is among the strongest clinical results published, providing powerful data for clinician education materials and presentations.
Clinical Use of Mesenchymal Stem Cells in the Treatment of Knee OA: A Meta-Analysis of Randomized Controlled Trials
Kim SH, Ha CW, Park YB, et al.BioMed Research International2019
Largest meta-analysis to date: 11 RCTs pooling 582 patients, with subgroup analyses by cell source, dose, and control type.
MSC injection significantly improved WOMAC pain (SMD -1.45, p<0.001), function (SMD -1.29, p<0.001), and stiffness (SMD -0.98, p=0.002). No difference in serious adverse event rates. ADSC and BM-MSC showed comparable efficacy.
NeoRegen Relevance: Level I evidence (meta-analysis of RCTs) confirming MSC efficacy for OA. The comparable efficacy of multiple tissue sources supports NeoRegen's perinatal-derived product strategy.
Phase III Trial of Allogeneic BM-MSC Therapy (Stempeucel) for Knee Osteoarthritis
Gupta PK, Chullikana A, Rengasamy M, et al.Stem Cell Research & Therapy2016
Landmark multicenter, randomized, double-blind, placebo-controlled Phase III trial—one of the first for any allogeneic MSC product in orthopedics. 60 patients.
Significant VAS pain improvement (17.2mm vs. 6.4mm placebo, p=0.013). Six-minute walk distance +48.7m vs. +12.3m placebo (p=0.009). No immune rejection or donor-specific antibody formation.
NeoRegen Relevance: Proves allogeneic (donor-derived) MSC products are safe and effective—no immune rejection despite HLA mismatch. Directly validates the allograft model for perinatal-derived regenerative products.
Intra-articular Injection of Human Umbilical Cord–Derived MSCs for Knee OA: A Dose-Escalation Phase I/II Trial
Matas J, Orrego M, Amenabar D, et al.Stem Cell Research & Therapy2019
First-in-human trial of umbilical cord-derived MSCs for knee OA. 26 patients across three dose groups of allogeneic UC-MSCs.
High-dose (40×10⁶): 65% WOMAC improvement at 12 months. VAS pain decreased 58%. MRI showed improved cartilage matrix quality. No serious adverse events or immune-mediated reactions.
NeoRegen Relevance: The most directly relevant study to NeoRegen's product strategy—perinatal tissue (umbilical cord) as the cell source, allogeneic delivery, demonstrated cartilage regeneration.
Stem cell research in neurosurgery focuses on spinal cord injury repair, intervertebral disc regeneration, and neuroprotection. These studies demonstrate how regenerative biologics are pioneering new approaches to neurological recovery where traditional treatments offer limited options.
1
Transplantation of Mesenchymal Stem Cells for Spinal Cord Injury: A Systematic Review and Network Meta-Analysis
Xu P, Yang X.Journal of Orthopaedic Translation2021
Network meta-analysis of 23 clinical studies comparing MSC sources and delivery routes for SCI.
BM-MSCs: greatest ASIA motor score improvement (mean +8.2 points). Intrathecal delivery comparable to direct injection with fewer complications (3.2% vs. 12.8%). Treatment within 6 months yielded 2.4x greater motor improvement.
NeoRegen Relevance: Intrathecal delivery equivalence reduces procedural risk and broadens the clinician population who can administer treatment.
Safety and Feasibility of Autologous BM-MSC Transplantation in Chronic Spinal Cord Injury
Mendonça MV, Larocca TF, de Freitas Souza BS, et al.Stem Cell Research & Therapy2014
Phase I safety study: 14 chronic SCI patients received intrathecal BM-MSCs with comprehensive 6-month monitoring.
Zero serious adverse events. No MRI evidence of tumor formation. 36% showed improved ASIA sensory scores. Only mild, self-limiting side effects (headache 36%, low-grade fever 21%).
NeoRegen Relevance: Establishes the critical safety foundation for MSC neurological applications with intrathecal delivery.
Intradiscal Injection of Autologous Mesenchymal Stem Cells for Degenerative Disc Disease
Orozco L, Soler R, Morera C, et al.Transplantation2011
Pioneering proof-of-concept: 10 patients with lumbar disc degeneration received single intradiscal BM-MSC injection.
VAS pain decreased 65% (69 to 24 mm). ODI disability improved 50%. MRI showed increased disc hydration in 8 of 10 patients. Disc height maintained in all patients.
NeoRegen Relevance: Opens the intradiscal regeneration market. MRI evidence of disc rehydration suggests true structural repair, aligning with NeoRegen's “restore, repair, and regenerate” mission.
Phase I/IIa Study of Intradiscal Allogenic Mesenchymal Stem Cells in Degenerative Disc Disease
Noriega DC, Ardura F, Hernandez-Ramajo R, et al.Transplantation2017
First controlled trial of allogeneic MSCs for disc degeneration. 24 patients randomized to BM-MSCs vs. sham, double-blind design.
71% VAS pain improvement vs. 33% sham (p<0.01). Disc hydration improved 18.4% on MRI only in MSC group. No immune rejection or donor-specific antibodies.
NeoRegen Relevance: Allogeneic safety confirmed for intradiscal use—critical for NeoRegen's off-the-shelf product model.
A First-in-Human Phase I Study of Neural Stem Cell Transplantation for Chronic Spinal Cord Injury
Curtis E, Martin JR, Gabel B, et al.Cell Stem Cell2018
Landmark Phase I/II trial: direct intramedullary injection of neural stem cells in 12 chronic thoracic SCI patients at escalating doses.
Safety established across all dose levels. 25% showed ASIA sensory improvement. Post-mortem analysis confirmed NSC engraftment and differentiation into mature neurons at injection site.
NeoRegen Relevance: Biological proof that cell-based spinal repair is achievable, validating the broader regenerative approach for neurosurgery applications.
NeoRegen Relevance: The paracrine mechanism suggests biological factors secreted by MSCs (preserved in minimally manipulated perinatal tissue) may be as important as the cells themselves.
Exosomes (30–150 nm extracellular vesicles) derived from mesenchymal stem cells represent a pioneering cell-free approach to joint repair. They carry bioactive cargo—miRNAs, proteins, growth factors—that modulate inflammation and promote cartilage regeneration, working in harmony with the body's natural processes.
1
Exosomes from Embryonic Mesenchymal Stem Cells Promote Cartilage Regeneration
Zhang S, Chuah SJ, Lai RC, et al.Theranostics2018
Foundational study demonstrating MSC-derived exosomes alone can drive cartilage regeneration in a rat osteochondral defect model.
Near-complete cartilage regeneration at 12 weeks (ICRS II score 14.2 vs. 5.1 control). Collagen II 3.4x higher. Inflammatory markers reduced 60–75%. Regenerated cartilage showed hyaline characteristics.
NeoRegen Relevance: Proves exosome-based therapy achieves cartilage regeneration comparable to whole-cell therapy. Major implications for simpler manufacturing and delivery.
Exosomes Derived from Human BM-MSCs Promote Cartilage Repair via the miR-92a-3p/WNT5A Axis
Mao G, Zhang Z, Hu S, et al.Stem Cell Research & Therapy2018
Identified miR-92a-3p/WNT5A signaling as the molecular mechanism of MSC exosome cartilage protection.
miR-92a-3p 15.3x enriched in MSC exosomes. WNT5A suppressed by 72%. In vivo: 58% less cartilage erosion and 3.2x more proteoglycan content vs. controls.
NeoRegen Relevance: miR-92a-3p levels could serve as a potency biomarker for exosome product quality control.
Immunosuppressive Properties of Mesenchymal Stem Cell-Derived Exosomes
Cosenza S, Toupet K, Maumus M, et al.Frontiers in Immunology2017
Key finding: MSC exosomes replicate the full immunosuppressive function of parent MSCs in a collagen-induced arthritis model.
Exosomes suppressed T cell proliferation by 75% (comparable to 78% for whole MSCs). TNF-α reduced 64%, IL-6 58%, IL-17 71%. Joint swelling reduced 62%, cartilage erosion 54%.
NeoRegen Relevance: Functional equivalence between exosomes and whole MSCs is foundational. Perinatal tissue processing that preserves the exosome fraction captures the core therapeutic mechanism.
SOX9 expression 4.1x increase. Collagen II 3.5x, aggrecan 2.9x. MMP-13 decreased 67%. In vivo: 51% less cartilage degradation. SOX9 knockdown abolished all protective effects.
NeoRegen Relevance: SOX9 activation is the gold standard for chondrogenic induction, connecting NeoRegen's products directly to the fundamental biology of cartilage formation.
Small Extracellular Vesicles from Human ADSCs Attenuate Cartilage Degeneration
Woo CH, Kim HK, Jung GY, et al.Journal of Extracellular Vesicles2020
Dose-dependent chondroprotective effects of adipose-derived small EVs. Proteomic analysis identified 1,847 proteins.
High-dose: 63% reduction in cartilage erosion, 71% proteoglycan preservation. Enrichment of TSG-6 and TGF-β1 in EV cargo. No adverse events at any dose.
NeoRegen Relevance: Dose-response data essential for product development. Specific therapeutic proteins (TSG-6, TGF-β1) provide measurable quality attributes for manufacturing.
Human UC-MSC-Derived Exosomes Enhance Cartilage Repair via TGF-β Signaling
Yan L, Wu X.Stem Cell Research & Therapy2019
Tested umbilical cord MSC-derived exosomes for cartilage repair with TGF-β pathway analysis.
TGF-β/Smad2/3 signaling activated (phospho-Smad2 3.8x). In vivo: 72% cartilage fill at 12 weeks vs. 28% controls. IL-1β and TNF-α reduced 68% and 59%.
NeoRegen Relevance: UC-MSC exosomes are most directly relevant to NeoRegen's perinatal-derived products. TGF-β mechanism provides a strong scientific narrative for clinician education.
Extracellular Vesicles for Musculoskeletal Regeneration: A Systematic Review
Murphy C, Withrow J, Hunter M, et al.Stem Cells Translational Medicine2020
Most comprehensive systematic review: 72 studies (62 preclinical, 10 clinical) on EV applications in bone, cartilage, tendon, and muscle.
94% preclinical efficacy rate for cartilage repair. Anti-inflammatory effects in 100% of studies measuring cytokines. Clinical pain improvement in 90% of patients.
NeoRegen Relevance: The 94% preclinical efficacy rate is remarkable consistency. Identified gaps (standardization, potency assays) represent challenges NeoRegen is positioned to address.
Nanoparticle-based drug delivery systems address the rapid clearance problem that limits conventional intra-articular injections. By encapsulating therapeutic agents in nanocarriers, joint residence time extends from hours to weeks—a pioneering approach to sustained, targeted treatment that complements regenerative biologics.
1
Intra-articular Drug Delivery Using Nanoparticle-Based Systems: A Comprehensive Review
Maudens P, Jordan O, Allémann E.Journal of Controlled Release2018
Definitive review of 120+ publications analyzing PLGA, liposomes, micelles, dendrimers, chitosan, and solid lipid nanoparticle systems.
Nanoparticle-Based Drug Delivery Systems for Intra-articular Injection of Knee OA
Kang ML, Ko JY, Kim JE, Im GI.International Journal of Molecular Sciences2014
Review of 45 studies on PLGA and chitosan nanoparticle systems for sustained delivery of anti-inflammatory drugs and growth factors.
PLGA NPs: 3–4 week sustained release vs. 4–6 hours free drug. Chitosan NPs: 2.3x longer retention. Growth factor NPs maintained 87% bioactivity at 21 days vs. 12% for free TGF-β. 4–8x improvement in joint drug levels at 2 weeks.
NeoRegen Relevance: Nanoparticle encapsulation of growth factors preserved in perinatal tissue could dramatically extend the therapeutic window of regenerative products.
Kartogenin-Loaded PLGA Nanoparticles for Intra-articular Cartilage Regeneration
Kang ML, Kim JE, Im GI.J Biomedical Materials Research A2017
PLGA nanoparticle encapsulation of kartogenin achieved sustained cartilage regeneration from a single injection in a rat OA model.
28-day sustained release vs. <6 hours free drug. SOX9 5.2x increase. 67% cartilage preservation vs. 31% free drug. Benefit persisted 8 weeks from single injection.
NeoRegen Relevance: Proves synergy between nanoparticle delivery and pro-chondrogenic agents, demonstrating potential of combining regenerative biologics with nanocarrier technology.
Lipid Nanoparticles for Delivery of Anti-Inflammatory Agents to Osteoarthritic Joints
Elron-Gross I, Glucksam Y, Margalit R.Journal of Controlled Release2009
Lipid nanoparticle encapsulation of dexamethasone and diclofenac in an adjuvant-induced arthritis model.
Joint retention improved 5-fold (half-life 5.2 days vs. 1.1 days). Dexamethasone-NPs reduced swelling 78% at day 14 vs. 31% free drug. TNF-α reduced 72%, IL-6 65%.
NeoRegen Relevance: The 5x retention improvement represents the difference between injections lasting days vs. weeks. Lipid NP formulations could carry bioactive factors from perinatal tissue.
pH-Responsive Polymeric Nanoparticles for Enhanced Intra-articular Drug Retention
Maudens P, Seemayer CA, Pfefferlé C, et al.European J Pharmaceutics & Biopharmaceutics2018
Smart nanoparticles that respond to acidic OA joint environment, swelling from 180nm to 450–600nm to prevent lymphatic clearance.
62% fluorescence retained at day 14 vs. 23% conventional NPs. 2.7x longer retention in arthritic vs. healthy joints. 71% swelling reduction vs. 42% conventional NPs.
NeoRegen Relevance: Disease-responsive delivery could enable products that selectively deliver regenerative factors to the most damaged areas of an osteoarthritic joint.
Biofunctional Polymer Nanoparticles for Intra-articular Targeting and Retention in Cartilage
Rothenfluh DA, Bermudez H, O'Neil CP, Hubbell JA.Nature Materials2008
Published in Nature Materials—engineering of nanoparticles with collagen II-binding peptides for cartilage-specific targeting.
Collagen II-binding peptide conjugation increased cartilage accumulation 72-fold over untargeted particles. Penetration depth reached the deep zone. Retention >14 days in joint space.
NeoRegen Relevance: Cartilage-targeting technology could be combined with NeoRegen's regenerative biologics for precise delivery to damaged tissue.
Biodegradable Nanoparticle Carriers for Intra-articular Drug Delivery
Alam MM, et al.International J Biological Macromolecules2022
Comprehensive analysis of biodegradable nanoparticle carriers for sustained intra-articular drug delivery in osteoarthritis.
Reviews the latest advances in PLGA, chitosan, and hybrid nanoparticle systems for joint-targeted delivery with sustained release profiles exceeding conventional formulations.
NeoRegen Relevance: Biodegradable carriers align with NeoRegen's commitment to products that work in harmony with the body's natural processes.
Mesenchymal stem cells derived from perinatal tissues show remarkable promise for neurodegenerative conditions including Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis. These studies span clinical trials, systematic reviews, and mechanistic research demonstrating the neuroprotective, anti-inflammatory, and regenerative properties of MSCs and their secreted exosomes in neurological disorders.
1
Clinical Potential and Current Progress of Mesenchymal Stem Cells for Parkinson’s Disease: A Systematic Review
Chen Y, Shen J, Ke K, Gu X.Neurological Sciences2020
Systematic review analyzing the mechanisms of action and therapeutic potential of MSC-based therapies for Parkinson’s disease, covering growth factor secretion, exocytosis, and neuroinflammation attenuation.
MSCs demonstrated the capacity to differentiate toward dopaminergic neurons and release neurotrophic factors including BDNF, GDNF, and NGF. The review found MSCs produce immunomodulatory, neuroprotective, angiogenic, and chemotactic molecules that collectively address multiple PD pathological pathways simultaneously.
NeoRegen Relevance: Establishes the multi-modal mechanism by which perinatal-derived MSCs can address Parkinson’s pathology—through both paracrine neuroprotection and immunomodulation—validating the therapeutic rationale for birth-tissue products in neurodegenerative indications.
Intracerebroventricular Injection of Human Umbilical Cord Blood Mesenchymal Stem Cells in Patients with Alzheimer’s Disease Dementia: A Phase I Clinical Trial
Kim HJ, Seo SW, Chang JW, et al.Alzheimer’s Research & Therapy2021
Phase I dose-escalation clinical trial in nine patients with mild-to-moderate Alzheimer’s disease dementia evaluating three repeated intracerebroventricular injections of human umbilical cord blood-derived MSCs (hUCB-MSCs) at low dose (1.0×10⁷ cells) and high dose (3.0×10⁷ cells).
AD biomarkers (total tau, phosphorylated tau, and Aβ42) decreased 1 day after each hUCB-MSC injection, then returned to baseline after 4 weeks. MSC-related markers (Galectin-3, sICAM-1, progranulin, GDF-15) showed reciprocal increases. No dose-limiting toxicity was observed. The procedure was deemed safe and feasible for further clinical development.
NeoRegen Relevance: Landmark clinical trial using umbilical cord blood-derived MSCs—the same perinatal tissue source NeoRegen utilizes—demonstrating safety in human AD patients and measurable biomarker modulation, directly supporting the translational path for birth-tissue regenerative products in neurodegeneration.
Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
Islam MA, Alam SS, Kundu S, et al.Journal of Clinical Medicine2023
Comprehensive systematic review and meta-analysis assessing the effectiveness and safety of MSC therapy in individuals diagnosed with multiple sclerosis, drawing from PubMed, Scopus, Cochrane, ScienceDirect, and Google Scholar databases.
Analysis found MSC therapy is safe, with 96.3% of studies reporting no serious adverse effects. Minor side effects included transient fever, headache, and mild injection-site reactions. MRI-based assessments indicated neural regeneration potential. The review established a strong safety profile supporting further controlled clinical trials in MS.
NeoRegen Relevance: The robust safety profile documented across multiple MS clinical studies reinforces the therapeutic safety of MSC-based products. MS represents a significant market opportunity where perinatal-derived MSCs’ immunomodulatory properties directly address the autoimmune neuroinflammation driving disease progression.
Mesenchymal Stromal Cells for the Treatment of Alzheimer’s Disease: Strategies and Limitations
Regmi S, Liu DD, Shen M, et al.Frontiers in Molecular Neuroscience2022
Comprehensive review from Stanford University evaluating the therapeutic strategies and current limitations of MSCs for Alzheimer’s disease, covering immunomodulatory, anti-inflammatory, regenerative, antioxidant, anti-apoptotic, and neuroprotective mechanisms.
MSCs secrete neuroprotective and anti-inflammatory factors that promote neuronal survival, transfer functional mitochondria and miRNAs to boost neuronal bioenergetic profiles, and improve microglial clearance of accumulated protein aggregates including amyloid-β plaques and tau tangles. The review identifies key challenges including optimizing delivery routes and ensuring long-term engraftment.
NeoRegen Relevance: Details the specific biological mechanisms through which MSCs combat AD pathology—particularly the paracrine secretion of neuroprotective factors and mitochondrial transfer—providing the scientific rationale for perinatal tissue-derived products in cognitive degeneration applications.
Neurological Efficacy and Safety of Mesenchymal Stem Cells (MSCs) Therapy in People with Multiple Sclerosis (pwMS): An Updated Systematic Review and Meta-Analysis
Vaheb S, Afshin S, Ghoshouni H, et al.Multiple Sclerosis and Related Disorders2024
Updated systematic review and meta-analysis encompassing 30 interventional studies analyzing MSC therapy efficacy across relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) patient populations.
Intrathecal MSC transplantation produced statistically significant improvement in Expanded Disability Status Scale (EDSS) scores (WMD −0.28; 95% CI −0.53 to −0.03; p=0.028). MRI-based assessments showed significant neural regeneration potential. The 30-study analysis confirmed a favorable safety profile with only transient, mild adverse events.
NeoRegen Relevance: The largest meta-analysis to date on MSC therapy in MS, demonstrating measurable clinical improvement via intrathecal delivery. The finding of disability scale improvement supports the disease-modifying potential of MSC-based therapies in autoimmune neurological conditions.
Human Wharton’s Jelly Mesenchymal Stem Cells Protect Neural Cells from Oxidative Stress Through Paracrine Mechanisms
Almeida C, Najar M, Auber-Thomay M, et al.Future Science OA2020
Mechanistic study evaluating the neuroprotective effects of Wharton’s jelly-derived MSCs (WJ-MSCs) and their extracellular vesicles (EVs) on rat hippocampal neuronal cultures subjected to hydrogen peroxide-induced oxidative stress.
Coculture with WJ-MSCs or pre-incubation with EVs significantly reduced reactive oxygen species (ROS) after H₂O₂ exposure. Cell viability was improved when coculture was maintained during the oxidative insult. The results demonstrate that WJ-MSCs exert antioxidant and neuroprotective effects on hippocampal neurons, partially mediated through extracellular vesicle paracrine signaling.
NeoRegen Relevance: Directly demonstrates the neuroprotective capacity of Wharton’s jelly MSCs—the exact perinatal tissue type used in NeoRegen products. The paracrine mechanism confirms that the bioactive factors secreted by these cells, not just the cells themselves, drive neuronal protection against oxidative damage.
Comprehensive review bridging preclinical evidence to clinical translation of umbilical cord-derived MSCs across Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and Huntington’s disease, examining the unique biological advantages of UC-MSCs for neurological applications.
UC-MSCs express superior levels of genes involved in neurogenesis and angiogenesis compared to adult-tissue MSCs. These cells release large amounts of BDNF, NT-3, and NGF, and demonstrate superior differentiation, migration, and neuroprotective properties. Collection is noninvasive, eliminates ethical concerns, and the cells exhibit low immunogenicity enabling allogeneic use without rejection.
NeoRegen Relevance: The definitive review establishing umbilical cord MSCs as the optimal source for neurological applications—directly validating NeoRegen’s perinatal tissue platform. Demonstrates that cord-derived MSCs outperform adult-tissue MSCs in neuroprotective factor secretion, differentiation potential, and clinical feasibility across multiple neurodegenerative diseases.
NeoRegen Biosciences harnesses donated birth tissue to develop high-quality regenerative products that restore, repair, and regenerate—accessible and affordable, without sacrificing standards.
Donor Screening
Comprehensive screening for communicable diseases with Medical Director review of every donation.
Tissue Collection
Full-term, planned cesarean births collected by licensed professionals under strict protocols.
48-Hour Processing
Gestational derived tissue processed within 48 hours in ISO-5 facilities and ISO-3 biosafety cabinets.
Preservation
Controlled slow-rate freezing at –80°C and eBeam (25kGy) sterilization to maintain biological integrity.
Quality Assurance
Every lot independently tested by third-party labs. Only lots passing USP <71> Sterility and USP <85> LAL Endotoxin Testing are cleared.
Secure Distribution
Products shipped in validated coolers overnight on dry ice with complete lot traceability throughout lifecycle.
